BioSpace News Archive

IRLAB Therapeutics Gothenburg, Sweden, February 6, 2024 - IRLAB Therapeutics AB is a company discovering and developing novel treatments for Parkinson’s disease.

Nicox SA announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024, a key ophthalmology conference which will be held from May 5 to May 9, 2024 in Seattle, WA, United States.

Orexo AB, announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

Vividion Therapeutics, Inc., announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.

Thermosome announced that it received clearance by the independent Data Safety Monitoring Board to proceed as planned with the dose escalation in its ongoing Phase I trial of its lead program THE001.

AlzeCure Pharma AB announced that an abstract on preclinical data with its lead drug candidate NeuroRestore ACD856 has been accepted for a poster presentation at AD/PD 2024, which will be held in Lisbon on March 5-9.

Curium announced that beginning Friday, April 5, 2024, Ioflupane I 123 Injection will be available for Friday patient administration in the US. This additional day of production allows customers to access the product and capitalize on early morning availability on a day not previously available from Curium.

Centene Corporation announced its financial results for the fourth quarter and year ended December 31, 2023.

Qorvis announces the appointment of Dr. Colleen Pietras, M.D., to the position of Chief Medical Officer.

GE HealthCare, a leading global precision care innovator, reported financial results for the fourth quarter ended December 31, 2023.